Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: Results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study

Journal of Clinical Sleep Medicine

Volumn 13, Issue 11, 2017, Pages 1289-1299

  Murphy, Patricia ^a   Moline, Margaret ^a   Mayleben, David ^b   Rosenberg, Russell ^c   Zammit, Gary ^d   Pinner, Kate ^e   Dhadda, Shobha ^a   Hong, Quan ^a   Giorgi, Luigi ^e   Satlin, Andrew ^a  

^a EISAI INC   (United States)

^b Community Research Inc ^*  (United States)

^c Neurotrials Research Inc   (United States)

^d Clinilabs Inc   (United States)

^e EISAI CO LTD   (Japan)

Author keywords

Bayesian method; Insomnia; Orexin receptor antagonists

Indexed keywords

LEMBOREXANT; PLACEBO; NEW DRUG; OREXIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BACKACHE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIGIT SYMBOL SUBSTITUTION TEST; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPNAGOGIC HALLUCINATION; INSOMNIA; KAROLINSKA SLEEPINESS SCALE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NIGHTMARE; PARASOMNIA; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SINGLE BLIND PROCEDURE; SLEEP DISORDER; BAYES THEOREM; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OREXIN RECEPTOR ANTAGONISTS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85034016593     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.6800     Document Type: Article

References (38)

1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health. 4th ed. Washington DC: American Psychiatric Association; 1994.
3. Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Med. 2009;10(9):952-960.
4. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19.
5. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia and the performance of US workers: results from the America Insomnia Survey. Sleep. 2011;34(9):1161-1171.
6. Neubauer DN. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med. 2007;3(5 Suppl):S11-S15.
7. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49-56.
8. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
9. Equihua AC, De La Herrán-Arita AK, Drucker-Colin R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol. 2013;4:163.
10. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.
11. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103-112.
12. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
13. Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5(1):34-40.
14. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol. 1999;14(5):287-303.
15. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243-266.
16. Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs. Pharmacol Rep. 2016;68(2):231-242.
17. Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther. 2015;9:6035-6042.
18. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259-267.
19. Walsh JK, Salkeld L, Knowles LJ, Tasker T, Hunneyball IM. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness. Sleep Med. 2010;11(1):23-30.
20. Ivanova A, Liu K, Snyder E, Snavely D. Insomnia and the performance of US workers: results from the America insomnia survey. Sleep. 2011;34(9):1161-1171.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
22. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
23. Bélanger L, Vallières A, Ivers H, Moreau V, Lavigne G, Morin CM. Metaanalysis of sleep changes in control groups of insomnia treatment trials. J Sleep Res. 2007;16(1):77-84.
24. McCall WV, D'Agostino R Jr, Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med. 2003;4(1):57-62.
25. Winkler A, Rief W. Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis. Sleep. 2015;38(6):925-931.
26. Bianchi MT, Williams KL, McKinney S, Ellenbogen JM. The subjective objective mismatch in sleep perception among those with insomnia and sleep apnea. J Sleep Res. 2013;22(5):557-568.
27. Carskadon MA, Dement WC, Mitler MM, Guilleminault C, Zarcone VP, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry. 1976;133(12):1382-1388.
28. Silva GE, Goodwin JL, Sherrill DL, et al. Relationship between reported and measured sleep times: the sleep heart health study (SHHS). J Clin Sleep Med. 2007;3(6):622-630.
29. Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150-155.
30. De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colin R. Narcolepsy and orexins: an example of progress in sleep research. Front Neurol. 2011;2:26.
31. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136-148.
32. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461-471.
33. Panneman MJ, Goettsch WG, Kramarz P, Herings RM. The costs of benzodiazepine-associated hospital-treated fall Injuries in the EU: a Pharmo study. Drugs Aging. 2003;20(11):833-839.
34. Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the onthe- road driving test. Curr Drug Saf. 2006;1(1):63-71.
35. Peever J, Luppi PH, Montplaisir J. Breakdown in REM sleep circuitry underlies REM sleep behavior disorder. Trends Neurosci. 2014;37(5):279-288.
36. Jaussent I, Dauvilliers Y, Ancelin ML, et al. Insomnia symptoms in older adults: associated factors and gender differences. Am J Geriatr Psychiatry. 2011;19(1):88-97.
37. Sivertsen B, Nordhus IH. Management of insomnia in older adults. Br J Psychiatry. 2007;190:285-286.
38. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-1350.